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Abstract
Background: Understanding where mutant CFTR is localised in airway epithelia is essential in guiding the best therapeutic
approach to correct the dysfunction of the CFTR protein. The widely held paradigm is that CF patients harbouring the
commonest mutation, CFTR-delF508, trap CFTR within the endoplasmic reticulum and target it for degradation. However
there are conflicting reports concerning expression and localisation of CFTR-delF508 in lung tissue. To attempt to resolve
this fundamental issue we developed a novel approach to measure CFTR-delF508 in the lower airways of patients who have
undergone lung transplantation for advanced CF. By sampling CF and non-CF epithelium simultaneously from the same
individual, confounding factors of different airway microenvironments which may have influenced previous observations
can be overcome.
Methods: Epithelia sampled by bronchial brushing above (CF) and below (non-CF) the bronchial anastomosis were stained
for CFTR and the localisation and level of expression assessed (n=12).
Results: There was no significant difference in the proportion of tall columnar cells showing CFTR immunostaining as a
discrete band at the apical membrane in cells harbouring the CFTR-delF508 mutation compared to non-CF cells (p=0.21,
n=12). However, the amount of CFTR expressed at the apical surface was reduced by ,50% in CF cells compared to non-CF
cells (p=0.04, n=5).
Conclusions: Our novel observation challenges the prevailing paradigm that CFTR is essentially absent from the apical
membrane of respiratory cells harbouring the CFTR-delF508 mutation. Moreover, it raises the possibility that the new
generation of CFTR potentiators may offer a realistic therapeutic option for CF patients.
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Introduction
Cystic Fibrosis (CF) is the most common autosomal recessive
disease in Caucasians and the most common heritable cause of
death during teenage and young adulthood [1]. CF is caused by
mutations in the gene encoding the cystic fibrosis transmembrane
conductance regulator (CFTR), a multidomain ATP-binding
cassette protein responsible for the regulation of transmembrane
transport of chloride and other ions. The most common mutation
is a deletion of a phenylalanine residue at position 508 (CFTR-
delF508), responsible for 70–80% of CF phenotype worldwide [2].
Current consensus is that this mutation leads to mislocalisation of
CFTR from the apical membrane [3]. Absence of CFTR chloride
secretion has been postulated to reduce airway surface liquid
volume and impair mucocillary clearance and innate defence
mechanisms [4]. These functional defects predispose the lungs to
bacterial infection, inflammatory destruction and eventual death
of the affected individual from respiratory failure.
The mislocalisation of CFTR has been observed in epithelial
tissues from the lung [3,5,6], intestine [7] and sweat glands [8]
under conditions of heterologous expression in culture, but also in-
vivo. However, the sensitivity of CFTR to its microenvironment
and the difficulties in accurately localising it has led to conflicting
reports and suggestions that localisation might differ between
tissues [7]. CFTR processing and localisation is also susceptible to
alterations in temperature [9,10], pH [11] and the presence of
micro-organisms [12,13]. Furthermore, the exact quantity of
normal-functioning CFTR needed at the apical membrane for
adequate function remains uncertain [14]. The correction of the
mislocalisation of mutant CFTR has been a therapeutic goal for
well over a decade and work continues to evaluate the role of gene
therapy in correcting the underlying defects [15]. More recently
there is increasing interest in the role of pharmacological agents
which may affect CFTR localisation in respiratory epithelium
[16,17,18,19,20]. To assess the efficacy of these approaches it is
critical to accurately determine the localisation of CFTR in the
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also to assess therapeutic interventions targeting CFTR.
To investigate CFTR localisation in the lower airway, we
developed a novel approach of sampling the lower respiratory
tract epithelia in CF patients who have undergone lung
transplantation. This approach allows both non-CF cells and cells
carrying the CFTR-delF508 mutation to be obtained from the
same airway microenvironment simultaneously. This approach
overcomes many of the significant limitations of previous studies,
and may provide a possible testing ground for novel therapies.
Materials and Methods
Ethics statement
The Newcastle and North Tyneside Local Regional Ethics
Committee approved the study (REC reference no 2001/179),
and written informed consent was obtained from each subject.
Characteristics of patients
Bronchial brushings were obtained using a protected specimen
single-sheathed nylon cytology brush (5 fr; Wilson-Cook) from at
least 2 cm above the airway anastomosis in the left main bronchus
and at least 2 cm below the airway anastomosis in the segmental
bronchus of the left lower lobe. Brushings were obtained from
twelve (8F:4M) lung transplant recipients between 79 and 357 days
post bilateral lung transplantation for advanced CF lung disease.
Standard immnuosuppression protocol after transplantation
comprises a calcineurin inhibitor (ciclosporin/tacrolimus), a cell
cycle inhibitor (azathioprine/mycophenolate mofetil) and oral
corticosteroids (maintenance dose 0.1 mg/kg). All subjects showed
no evidence of infection or acute or chronic rejection (grade A2 or
above (ISHLT classification) and were bronchiolitis obliterans
syndrome stage 0 (FEV1 .90% of baseline)).
CF mutation analysis
See Supporting Information S1. Briefly, genomic DNA was
extracted from cells using the Q-Card EZ1 DNA Tissue kit
according to manufacturer’s protocol (Qiagen). Genomic DNA
was analysed for 28 CF mutations using the CF-HTv3 kit (Tepnel).
Following amplification, separation and detection of products was
performed on an ABI PRISM 3130xl Genetic Analyser and data
analysed using Genemapper v3.7 (Applied Biosystems).
Immunofluorescence
Cells isolated by bronchial brushing were smeared onto
microscope slides and fixed with 4% paraformaldehyde. Cells
were incubated with either MATG1061 (raised against amino
acids 503–515 in the N-terminal) (RD-Biotech), 570 (raised against
amino acids 731–742 in the R-domain) or 596 (raised against
amino acids 1204–1211 in nucleotide binding domain 2) (both
Cystic Fibrosis Foundation) anti-CFTR monoclonal antibodies
and anti-Interferon regulatory factor-1 (IRF-1 - Santa Cruz) or
anti-b-tubulin polyclonal antibodies (Sigma). Antigen-antibody
complexes were detected using appropriate flourochrome-linked
secondary antibodies with DAPI as a nuclear counterstain. Laser
settings for each patient were optimised using the non-CF cells and
the same settings used to compare CFTR expression in the CFTR-
delF508 cells. Images acquired using a Leica TCS-SP-2UV laser
scanning confocal microscope. Isotype matched immunoglobulins
were employed as negative controls.
Statistical Analysis
The percentage of tall columnar epithelial (TCE) cells expressing
CFTR as a distinct apical band was examined in multiple randomly
selected fields and compared above and below the airway
anastomosis from each individual. Patients with ,100 cells were
excluded. Results were validated by counts from two blinded
individuals. Total and average pixel intensity of CFTR staining was
quantified using Photoshop CS3 (Adobe) in multiple randomly
selected fields and compared above and below the airway
anastomosis from each individual. At least 20 cells/sample were
assessed. The difference between groups was assessed by a one way
ANOVAusingSPSS14.0.Differenceswithap-valueof,0.05were
considered statistically significant.
Human Lung Tissue Sampling
Normal control tissue was obtained from unused donor lungs.
Lung samples were fixed in 10% formalin, embedded, sectioned
and stained with antibodies against E-cadherin (BD Bioscience)
and CFTR (RD-Biotech). Antibodies were detected using
appropriate flourochrome-linked secondary antibodies with DAPI
as a nuclear counterstain. Areas of intact epithelium were
identified and images acquired using a LSM 510 laser scanning
confocal microscope. Isotype matched immunoglobulins were
employed as negative controls.
Results
To investigate CFTR expression in both non-CF and CF cells
from the lower airway in the same individual, epithelia were
sampled by bronchial brushing from above (CFTR-delF508
mutation) and below (non-CF) the airway anastomosis joining
the native bronchus and the transplanted lung (Fig. 1A). Cells from
above the anastomosis were confirmed to be 100% homozygous
for the CFTR-delF508 mutation by genetic analysis. CFTR
protein expression and distribution was investigated using a well
validated anti-CFTR monoclonal antibody, MATG1061. To aid
identification and counting we co-stained the cytoplasm of the cells
with IRF-1, a transcription factor that is localised throughout the
cytoplasm of epithelial cells, as well as DAPI to stain the nucleus.
Consistent with previous results using the MATG1061 antibody in
freshly isolated nasal and bronchial epithelia cells [3,5,21] and
freshly excised human tissue [7,22] we found that the majority of
non-CF cells showing a strong CFTR signal were TCE cells and
CFTR appeared as a discrete band at the apical pole (Fig. 1B).
Further analysis showed that the apical CFTR band was located
just below the cilia (Fig. 1C) and that staining was absent in isotype
matched immunoglobulins negative controls (Fig. 1D). A similar
localisation was observed in the superficial epithelium of explanted
lung tissue from a non-CF patient (red staining in Fig. 2).
To quantify the number of non-CF and CF TCE cells
expressing CFTR at the apical pole we collected data from at
least 100 cells/sample, and the number of CFTR positive cells was
quantified by two blinded observers. An example of a typical
image is shown in figure 3A. These images show a group of ,40
cells and it can clearly be seen that the majority of TCE cells
express a clear apical band for CFTR in both samples. Mean data
from twelve lung recipient patients with CF collected in an
identical way is presented in figure 3B. Results show that there was
no significant difference in the percentage of TCE cells expressing
apical CFTR above and below the airway anastomosis (Fig. 3Bi).
Eight of the twelve lung transplant recipients were CFTR-delF508
homozygous and four were CFTR-delF508 heterozygous. In all
cases for the individuals heterozygous for the CFTR-delF508
mutation the second mutant allele differed making it difficult to
analyse the data as one group as it would be very difficult to
interpret any findings with confidence due to the possible effects of
the different 2
nd mutations on CFTR localisation/expression
CFTR-delF508 Expression in the Lower Airway
PLoS ONE | www.plosone.org 2 August 2011 | Volume 6 | Issue 8 | e23226Figure 1. The post transplant lung in a CF patient; a novel way to investigate CFTR localisation. A) Bronchial brushings (example shown
in the upper right panel) from post transplant CF patients allowed both CFTR-delF508 affected epithelial cells (above the airway anastomosis from
the native tissue) and non-CF epithelial cells (below the airway anastomosis from the donor lung) to be obtained from the same patient and
investigate CFTR localisation and expression levels. B+C) Bronchial brushings of non-CF cells fixed in 4% paraformaldehyde and stained for CFTR
(MATG1061 - FITC/Green) and IRF-1 (B) or b-tubulin (C) (TRITC/Red) with a nuclear counter stain (DAPI/Blue). CFTR is localised predominantly to the
apical membrane of tall columnar epithelial cells. Images acquired on a Leica confocal microscope (6100 magnification). D) Corresponding isotype
control. CFTR (MATG1061) was replaced by IgG2a at the corresponding concentrations. No non-specific staining was seen in tall columnar epithelial
cells. Images acquired on a Leica confocal microscope (663 magnification).
doi:10.1371/journal.pone.0023226.g001
Figure 2. CFTR expression in explanted lung tissue. A) Explanted non-CF lung tissue was stained for CFTR (MATG1061 - TRITC/Red) and the
epithelial marker E-cadherin (FITC/Green) with a nuclear counter stain (DAPI/Blue). CFTR is expressed only at the apical membrane of airway epithelial
cells. Images acquired on a Leica confocal microscope (640 magnification). B) Image acquired in A) showing CFTR (TRITC/Red) staining only.
doi:10.1371/journal.pone.0023226.g002
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PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e23226Figure 3. CFTR is expressed apically in CFTR-delF508 affected epithelial cells. A) Example of bronchial brushings of non-CF (i) and CFTR-
delF508 (ii) affected epithelial cells fixed in 4% paraformaldehyde and stained for CFTR (MATG1061 - FITC/Green) and IRF-1 (TRITC/Red) with a nuclear
counter stain (DAPI/Blue). Quantification displayed refers to the specific patient the images were acquired from. Images acquired on a Leica confocal
CFTR-delF508 Expression in the Lower Airway
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undergo transplantation it would be extremely difficult to generate
sufficient data sets to achieve significance using any individual
second mutation.
Consequently we analysed the results from CFTR-delF508
homozygous patients alone. Again, there was no significant
difference in the percentage of TCE cells expressing apical CFTR
above and below the airway anastomosis (Fig. 3bii). These results
clearly indicate that the proportion of cells expressing a distinct
band of apical CFTR is not different between non-CF and CFTR-
delF508 CF cells.
To confirm the results above with the MATG1061 antibody we
proceeded to compare the number of non-CF and CF TCE cells
expressing CFTR at the apical pole with 2 further well
characterised [23,24] CFTR monoclonal antibodies (570 and
596) in a single patient (Fig. S1). We found that the percentage of
TCE cells expressing CFTR at the apical pole above and below
the airway anastomosis was very similar using all 3 antibodies
(MATG1061: 74% vs 72%, 570: 70% vs 66%, 596: 64% vs 67%)
confirming the accuracy of the MATG1061 antibody.
The finding that CFTR was detected in the same proportion of
non-CF and CF lower airway cells was unexpected since impaired
trafficking of CFTR-delF508 is thought to be the hallmark of CF
in airway epithelial cells [3]. However, the CFTR-delF508
mutation has also been shown to reduce protein stability at the
cell surface [23] and may therefore decrease the quantity of
mutant protein at the apical membrane. To investigate this
possibility we used image analysis software to quantify the signal
intensity of the apical band of CFTR. We analysed at least 20
cells/sample from non-CF (Fig. 4Ai) and CF (Fig. 4Aii) cells and
calculated the average and total pixel intensity for each isolated
apical band (Fig. 4B). In contrast to the data on the proportion of
CFTR positive cells, we found a significant reduction in both the
average (Fig. 4Bi) and total (Fig. 4Bii) pixel intensity of CFTR
staining at the apical membrane of CF cells compared to non-CF
cells. These results, together with the data in figure 3, strongly
suggest that the CFTR-delF508 protein in lower airway TCE cells
does not exhibit a major trafficking defect per se, but the mutation
does markedly reduce the quantity of protein localised to the
membrane.
Discussion
The rationale for developing gene therapy and small molecule
drug corrector approaches to treat CF lung disease is the reported
absence of CFTR from the apical membrane of airway epithelium
in the commonest mutation, CFTR-delF508. This is believed to
occur due to inefficient biosynthetic maturation of the mutant
protein and its rapid degradation via the endoplasmic reticulum-
associated degradation pathway (ERAD) [25,26]. This paradigm is
based historically on in vitro studies in cells expressing exogenous
mutant CFTR as well as CFTR localisation studies in both fixed
excised lung tissue and cultured nasal epithelium [3,5,6,27]. These
studies, however, have significant limitations due to overexpression
and processing artefacts and inherent microenvironmental differ-
ences between the CF and non-CF airway which may influence
CFTR localisation and expression. Indeed recent studies have
shown that endogenous CFTR is processed and trafficked
differently to exogenous CFTR [28] and that processing and
function of CFTR is species dependant [29]. Typically, only nasal
epithelium is sampled in vivo in CF patients, and uncertainty exists
as to the relation of CFTR expression in the upper and lower
airway. We therefore developed a novel approach which
overcomes these problems to assess CFTR localisation in lower
airway epithelial cells from patients who have undergone lung
transplantation for advanced CF.
Cells brushed from above the bronchial anastomosis in CFTR-
delF508 homozygous individuals were confirmed to be 100%
CFTR-delF508 homozygous and those from below were con-
firmed non-CF. We found no significant difference in the
percentage of TCE cells expressing apical CFTR when sampled
from below (non-CF) and above (CFTR-delF508) the airway
anastomosis. However, apical CFTR staining showed a significant
reduction in both average and total pixel intensity in CFTR-
delF508 affected cells compared to non-CF cells. This suggests
that, when TCE cells are isolated from the same airway
microenvironment, an equal proportion of CFTR-delF508 and
non-CF cells express CFTR at the apical membrane. In contrast to
some previous reports, the quantity of CFTR expressed at the
apical membrane of TCE cells was the only distinguishing feature
in the lower airway.
There have been conflicting reports regarding CFTR expres-
sion in excised native airway tissues. Using the same antibody as in
the present study, frozen sections of excised nasal polyps were
shown to express CFTR predominantly in the apical membrane
and sub-membranous compartment of ciliated epithelial cells. This
pattern of expression was also seen in CFTR-delF508 homozygous
tissues, but with additional accumulation along the basolateral and
mitochondrial membranes [6]. This antibody was raised against a
synthetic peptide corresponding to amino acid position 503–515
and has been repeatedly shown to identify normal and CFTR-
delF508 equally [3,5,6]. In keeping with our findings, Kalin et al
also found indistinguishable levels of CFTR expression in
pseudostratified columnar epithelium covering nasal polyps, and
in submucosal glands of nasal polyps [7]. This study included
cellular localisation and signal intensity analysed by immunohis-
tochemistry. Only submucosal gland CFTR expression was
analysed in bronchial tissue and was found to be indistinguishable
in CF and non-CF individuals. The same study found CFTR
expression undetectable in bronchial specimens using the
MATG1061 antibody. The specificity of this antibody has also
been questioned, after non-specific staining was demonstrated in
sweat glands [8]. It has, however, been pointed out that the anti-
alkaline phosphatase method used in preference of immunofluo-
rescence by these authors may have resulted in a decrease in
specificity [5]. Antibodies raised to other domains of CFTR have
delivered contrasting results. Using an antibody raised to a C-
terminal peptide (residues 1468–1480) Engelhardt et al found no
evidence of CFTR protein expression in the bronchial surface
epithelium, apart from localised expression in a small number of
flask-like cells [30]. The expression of CFTR was limited to the
submucosal glands in frozen bronchial tissue specimens, and
completely absent in CFTR-delF508 homozygous individuals. In
microscope (620 magnification). B) Quantification of the percentage of tall columnar epithelial cells positive for CFTR at the apical membrane. i) All
patients (CFTR-delF508 homozygous patients (N=8) and CFTR-delF508 heterozygous patients (N=4)). No significant difference in the percentage of
cells expressing CFTR at the apical membrane was seen in non-CF (6863%) and CF (7163%) epithelial cells (p=0.21, N=12). ii) CFTR-delF508
homozygous patients only (N=8). No significant difference in the percentage of cells expressing CFTR at the apical membrane was seen in non-CF
(6763%) and CFTR-delF508 homozygous affected (7163%) epithelial cells (p=0.14, N=8). There was also no significant difference in the total
number of cells quantified (p=0.48, N=8).
doi:10.1371/journal.pone.0023226.g003
CFTR-delF508 Expression in the Lower Airway
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of NBD2, Kreda et al found no evidence of expression of CFTR-
delF508 CFTR in TCE cells of human bronchial cryosections
obtained from homozygous individuals despite detecting CFTR
expression in the same cells from non-CF tissue [24].
Studies utilising detached airway epithelial cells, in particular
nasal epithelial cells, have generally demonstrated identifiable
differences in CFTR expression between CFTR-delF508
homozygous and non-CF individuals. Penque et al. found
CFTR to be localised mainly in the apical region of ciliated
and non-ciliated TCE cells [3]. Using 3 different antibodies,
including MATG1061, apically localised CFTR was identified
in 22% of CFTR-delF508 homozygous individuals, 42% of
heterozygotes and 56% in healthy individuals. Carvalho-
Oliveira et al. confirmed these findings using a panel of 7 anti-
CFTR antibodies and a range of processing and fixation
techniques [5]. Dormer et al found a distinct peri-nuclear
staining in TCE cells obtained by nasal brushing from CFTR-
delF508 homozygous individuals, and similar proportional
expression of apical CFTR from CF/non-CF individuals [27].
The former finding could not be confirmed by Carvalho-
Oliveira et al. using the same antibody and fixation technique
[5]. Our analysis of CFTR expression in TCE cells from the
lower airway therefore suggests a marked difference in
localisation between the upper and lower airway, when taken
together with these previous reports.
A possible alternative explanation for our findings is that the
particular microenvironment in the transplanted lung may correct
the CFTR-delF508 trafficking defect. Pharmacological therapy is
common in the lung transplant recipient, particularly the use of
various immunosuppressants, and this may affect CFTR matura-
tion and trafficking. Ciclosporin has been demonstrated to correct
processing mutations of other ATP-binding cassette proteins,
particularly P-glycoprotein, but failed to demonstrate any such
effect in cell lines expressing CFTR-delF508 [31,32]. However, no
direct evidence of an increased expression in response to any of the
other commonly used immunosuppressive agents exists.
Our novel observation challenges the prevailing paradigm that
CFTR is essentially absent from the apical membrane of
respiratory cells in CF patients harbouring the CFTR-delF508
mutation. Instead these data suggest that CFTR is widely
expressed at the apical membrane in epithelial cells from the
lower airway but at a significantly reduced level compared to non-
CF cells. This raises the exciting possibility that the new generation
of drugs which potentiate mutant CFTR activity [33,34,35] may
offer a realistic therapeutic option for CF patients, obviating the
need for gene therapy.
Supporting Information
Figure S1 Comparison of CFTR localisation using 3
different CFTR antibodies. Bronchial brushings of non-CF
and CF cells were stained for CFTR (left panel: MATG1061,
centre panel: 570, right panel: 596, (Cystic Fibrosis Foundation
(CFF)) - FITC/Green) and IRF-1 (TRITC/Red) with a nuclear
counter stain (DAPI/Blue). CFTR is localised predominantly to
the apical membrane of tall columnar epithelial cells in both non-
CF and CF cells for all 3 antibodies tested. Images acquired on a
Leica confocal microscope (620 magnification).
(TIF)
Supporting Information S1 Supplementary Material and
Methods.
(DOCX)
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